Actemra - (80mg/4mL, 200mg/10mL, 400mg/20mL; Injection, Intravenous)

Generic Name	tocilizumab	**Innovator**	Genentech, Inc.
Dosage	80mg/4mL, 200mg/10mL, 400mg/20mL; Injection, Intravenous	**Branded US Sales**	More Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	Less Than 5
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of Rheumatoid Arthritis : Adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.